Waters Integrates Acquisitions: Strong Synergies Drive Q1 Growth (WAT Q1 2026 Earnings Call)

By Dr. Graph | Updated on May 31, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Waters Corporation initiated a powerful new era of expansion in the first quarter of 2026, driven by rapid integration of acquired Biosciences and Diagnostic Solutions segments alongside strong legacy performance. CEO Udit Batra highlighted that legacy operations achieved double-digit organic constant currency growth, while newly acquired businesses outperformed management guidance. Bolstered by early operational improvements under a 180-day growth plan, the combined company achieved strong margin expansion and double-digit adjusted earnings growth. This initial success empowered management to raise the full-year organic constant currency revenue growth and adjusted earnings outlook, establishing a robust baseline for mid-teens long-term earnings growth.

Combined Operations Generate Solid Top-Line Outperformance and Double-Digit Earnings Growth

Waters Corporation reported total first-quarter revenue of $1.267 billion, exceeding expectations through immediate execution synergy following the recent closing of the transaction. Legacy organic operations contributed $747 million of this total, representing strong constant currency growth of 11% driven by robust instrument replacement.

Driven by top-line outperformance and operating efficiencies, adjusted earnings per share rose 20% to $2.70 to beat the guidance ceiling. Total company adjusted gross margin improved to 54.7% due to effective supply chain management and pricing discipline.

Raised Full-Year Guidance Reflected Strong Integration Synergies and Margin Confidence

Reflecting first-quarter strength, Waters raised its full-year 2026 organic constant currency revenue growth guidance to a range of 6.5% to 8% to reflect cross-selling momentum. CEO Udit Batra stated: "We delivered an excellent first quarter as a combined company, marking the start of a new powerful era of growth across our 4 divisions."

Consequently, full-year adjusted earnings per share guidance was raised by $0.10 to a range of $14.40 to $14.60 per share. CFO Amol Chaubal explained that restructuring actions will support margin progression in the second half of the year.

Legacy Analytical Sciences and Acquired Segments Capture Market Share Through Innovative Offerings

The legacy Analytical Sciences division generated revenue of $607 million, representing a 14% reported increase driven by robust instrument replacement. The Biosciences division achieved strong sales under new ownership supported by Europe-led demand for FACSDiscover systems, while Diagnostic Solutions delivered $288 million of revenue ahead of the BACTEC launch.

Commercial Integration Initiatives Drive Operational Visibility and Mitigate Macro Headwinds

CFO Amol Chaubal clarified that the raised acquired revenue synergies of $35 million exclude early pricing benefits, while modeling a prudent 6% organic constant currency growth rate for the second half of the year. Udit Batra highlighted that a comprehensive contract audit in the U.S. Diagnostic Solutions business identified approximately 700 contracts out of compliance.

Frequently Asked Questions

What drove the first-quarter revenue outperformance in the newly acquired segments?

The outperformance was driven by rapid commercial initiatives launched immediately after the February 9 closing date. The combined company increased the frequency and rigor of forecast and funnel reviews, while establishing new deal desks to deploy pricing discipline across the acquired Biosciences and Diagnostic Solutions divisions.

How is the company addressing export complexities and improving market access in China?

Waters approved localized manufacturing of Flow research instruments in China to compete for local tenders and mitigate export constraints. Reagent distribution is being optimized by leveraging the legacy commercial network to improve delivery speed to customers.

What clinical advantages does the next-generation BACTEC FXI system offer to microbiology labs?

The BACTEC FXI blood culture system combines advanced automation with a 3-hour faster detection time than prior generations. This regulatory milestone was achieved ahead of schedule, enabling earlier commercial launches across major European and Japanese markets.